Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from AN2 Therapeutics, Inc. ( (ANTX) ) is now available.
On April 9, 2026, AN2 Therapeutics entered into an Open Market Sale Agreement with Jefferies that allows the company to issue and sell up to $80 million of its common stock from time to time via at-the-market offerings on Nasdaq or other existing trading markets. Under the agreement, Jefferies will act as sales agent using commercially reasonable efforts, receive a commission of up to 3% of gross proceeds, and the arrangement will terminate once all shares are sold or upon prior written notice from either party.
Also on April 9, 2026, AN2 Therapeutics terminated its prior at-the-market sales agreement originally entered with Cowen and Company and later assigned to TD Securities, under which it had previously sold 2,502,000 shares for aggregate proceeds of about $20 million. The shift to a new ATM facility with Jefferies signals a continued reliance on equity financing to support corporate needs, while closing the earlier agreement formalizes the transition in the company’s capital-raising partnerships.
The most recent analyst rating on (ANTX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on AN2 Therapeutics, Inc. stock, see the ANTX Stock Forecast page.
Spark’s Take on ANTX Stock
According to Spark, TipRanks’ AI Analyst, ANTX is a Neutral.
The score is held back primarily by weak financial performance (no revenue, ongoing losses, and negative free cash flow despite a low-debt balance sheet). Technicals are a relative positive with a bullish longer-term trend and neutral momentum. Valuation remains constrained by losses (negative P/E) and the absence of a dividend.
To see Spark’s full report on ANTX stock, click here.
More about AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for infectious diseases, with its common stock listed on the Nasdaq Global Select Market. The company accesses public equity markets to fund its operations and advance its clinical and commercial programs within the healthcare and life sciences sector.
Average Trading Volume: 1,396,180
Technical Sentiment Signal: Buy
Current Market Cap: $120M
Learn more about ANTX stock on TipRanks’ Stock Analysis page.